CARLSBAD, Calif., March 5 /PRNewswire-FirstCall/ -- Micromet, Inc. , a biopharmaceutical company focusing on the development of novel, proprietary antibody-based products for cancer, inflammatory and autoimmune diseases, today announced that the Company will conduct a conference call and audio webcast on Wednesday, March 14, 2007, at 10:00am Eastern Time (04:00pm Central European Time) in conjunction with the release of its financial results for the fourth quarter and year ended December 31, 2006. Micromet anticipates releasing its financial results at 7:00am, Eastern Time (01:00pm Central European Time) on Wednesday, March 14, 2007.
To participate in this conference call, dial 866-713-8565 (U.S.) or 617-597-5324 (international), passcode: Micromet. The audio webcast can be accessed at: www.micromet-inc.com.
A replay of the call will be available from 12:00pm Eastern Time on March 14, 2007 (06:00pm Central European Time) through Wednesday, March 21, 2007. The replay number is 888-286-8010 (U.S.) or 617-801-6888 (international), passcode: 53343055.
About Micromet, Inc. (www.micromet-inc.com)
Micromet, Inc. is a biopharmaceutical company focusing on the development of novel, proprietary antibody-based products for cancer, inflammatory and autoimmune diseases. Two product candidates are currently in clinical trials. MT103 (MEDI-538), which is the first product candidate based on Micromet's novel BiTE(R) product development platform, is being evaluated in a phase 1 clinical trial for the treatment of patients with non-Hodgkins lymphoma. The BiTE(R) product development platform is based on a unique, antibody-based format that leverages the cytotoxic potential of T cells, the most powerful 'killer cells' of the human immune system. Adecatumumab (MT201), a recombinant human monoclonal antibody which targets EpCAM expressing tumors, has completed two phase 2a clinical trials, one in patients with breast cancer and the other in patients with prostate cancer. In addition, a phase 1b trial evaluating the safety and tolerability of MT201 in combination with docetaxel is currently ongoing in patients with metastatic breast cancer. Micromet has established collaborations with MedImmune and Merck Serono.
Micromet, Inc.CONTACT: Christopher Schnittker, SVP & CFO, Micromet, Inc.,+1-760-494-4238, cschnittker@micromet-inc.com; Investors: Susan Noonan -U.S., +1-212-966-3650, susan@sanoonan.com, or Ines-Regina Buth - Europe,+49-30-2363-2768, ines@akampion.com; or Media: Patricia Garrison - U.S.,+1-917-322-2567 pgarrison@rxir.com, or Evelyn Wolf - Europe,+49-89-4445-2099, evelyn@akampion.com, all for Micromet, Inc.
Web site: http://www.micromet-inc.com/
